Kalaris Therapeutics (NASDAQ:KLRS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Kalaris Therapeutics (NASDAQ:KLRS) from a sell rating to a hold rating in a research report report published on Saturday morning.

Several other brokerages have also recently commented on KLRS. Citigroup reiterated an “outperform” rating on shares of Kalaris Therapeutics in a research report on Thursday, December 18th. Citizens Jmp initiated coverage on Kalaris Therapeutics in a research note on Monday, November 3rd. They set a “market outperform” rating and a $20.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Kalaris Therapeutics in a research note on Monday, December 29th. Finally, Chardan Capital began coverage on Kalaris Therapeutics in a report on Tuesday, December 23rd. They set a “buy” rating and a $19.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $14.00.

Kalaris Therapeutics Price Performance

KLRS opened at $10.77 on Friday. The firm has a 50 day simple moving average of $9.27 and a 200 day simple moving average of $6.49. Kalaris Therapeutics has a fifty-two week low of $2.14 and a fifty-two week high of $12.90. The company has a market cap of $201.40 million, a price-to-earnings ratio of -2.86 and a beta of -0.09.

Insiders Place Their Bets

In other Kalaris Therapeutics news, Director Srinivas Akkaraju bought 479,847 shares of the firm’s stock in a transaction on Thursday, December 18th. The stock was purchased at an average cost of $10.42 per share, with a total value of $5,000,005.74. Following the completion of the purchase, the director owned 1,979,847 shares in the company, valued at approximately $20,630,005.74. The trade was a 31.99% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 74.99% of the company’s stock.

Hedge Funds Weigh In On Kalaris Therapeutics

Several institutional investors have recently modified their holdings of the business. XTX Topco Ltd acquired a new position in shares of Kalaris Therapeutics in the 2nd quarter valued at approximately $65,000. Fortis Capital Advisors LLC bought a new position in Kalaris Therapeutics in the third quarter valued at approximately $231,000. Belpointe Asset Management LLC acquired a new position in shares of Kalaris Therapeutics in the third quarter valued at approximately $231,000. Johnson Financial Group Inc. acquired a new position in shares of Kalaris Therapeutics in the third quarter valued at approximately $58,000. Finally, Bridgeway Capital Management LLC bought a new stake in shares of Kalaris Therapeutics during the third quarter worth $130,000. Institutional investors own 66.05% of the company’s stock.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.